Hook & thesis
Rocket Lab has crossed an inflection point. Recent operating results and a beefy backlog show the company scaling its launch and space-systems business while management prepares for the Neutron reusable rocket’s maiden flight by the end of 2026. Those facts alone don’t make this a slam-dunk, but they do justify upgrading RKLB to a buy from a trading standpoint: the business is growing, the balance sheet is manageable, and a string of upcoming catalysts can re-rate the stock if milestones are met.
We’re initiating a long trade with a clear entry at $116.00, a stop loss at $95.00 to limit downside on near-term execution risk, and a target of $150.00 tied to upside toward the 52-week high should Neutron milestones and backlog conversion proceed on plan. This is a long-term trade meant to capture both operational progress and sector momentum, not a short-term momentum punt.
Business overview - what Rocket Lab does and why it matters
Rocket Lab operates two core segments: Launch Services and Space Systems. Launch Services offers dedicated and rideshare launches for small- and medium-class payloads, while Space Systems designs and manufactures spacecraft, components, and on-orbit mission services. The company’s strategy is to combine recurring revenue from launches with higher-margin, longer-duration Space Systems contracts to build a more predictable revenue base.
Why should the market care? Two reasons: first, franchise demand for small-satellite launches is structural as LEO broadband and Earth-observation constellations scale; second, Neutron — a reusable medium-class vehicle — represents a potential step-change in addressable market and per-launch economics if testing goes well. With the small satellite market expected to grow materially through the next decade, a successful Neutron program would position Rocket Lab beyond the niche-launcher category.
Key numbers supporting the thesis
| Metric | Value |
|---|---|
| Current price | $115.85 |
| Market cap | $67,061,798,691 |
| Q1 2026 revenue | $200,000,000 (63.5% YoY growth) |
| Backlog | > $2,000,000,000 |
| Free cash flow (TTM/latest) | -$316,301,000 |
| EPS (trailing) | -$0.32 |
| Enterprise value | $70,233,591,017 |
Two numbers stand out: the $200M in quarterly revenue (reported 05/31/2026) showing 63.5% year-over-year growth, and a backlog exceeding $2B. Backlog conversion — the process of turning booked launches and services into recognized revenue — is the immediate path to sustained top-line growth. The company’s enterprise value of roughly $70.2B and market cap near $67.1B show the market is already pricing in significant future progress; this trade is a bet that the company will deliver enough operational wins to justify that pricing over the next 180 trading days.
Valuation framing
At today’s price of $115.85, valuation metrics look aggressive on surface measures: price-to-sales and price-to-book are outsized versus legacy aerospace names (price-to-book around 31x in available metrics and price-to-sales reported materially elevated). Those multiples reflect both high expected growth and the scarcity value of a space-focused company with a reusable vehicle roadmap.
Put another way: the company is priced like a high-growth tech name more than a capital-intensive aerospace contractor. That’s reasonable if Neutron meaningfully expands addressable markets and improves per-launch economics, but it also increases binary risk - the market will re-rate hard in either direction around Neutron milestones and quarterly execution.
Catalysts (the events that could re-rate RKLB)
- Neutron flight test program progress and maiden flight execution (expected by end of 2026) - successful tests would be a major de-risking event.
- Backlog conversion into recognized revenue across the next several quarters - turning $2B+ of backlog into launches and service revenues will materially tighten the revenue story.
- Sector re-rating from SpaceX’s IPO and renewed investor interest in space equities - a public SpaceX provides a valuation reference and could lift sector multiples.
- Quarterly revenue and margin improvements - Q1 showed $200M and 63.5% YoY growth; repeating that cadence or accelerating margins will validate premium valuation.
Trade plan - entry, stop, target, and horizon
This is an actionable trade with specific risk controls:
- Entry: $116.00
- Stop loss: $95.00
- Target: $150.00
- Time horizon: long term (180 trading days)
Rationale: The entry is set just above current trading levels to capture momentum after any short-term consolidation. The stop at $95.00 sits beneath key moving averages and provides room for volatility while capping downside to a level inconsistent with the constructive base case. The target of $150.00 is anchored to the recent 52-week high and reflects upside if the Neutron program and backlog conversion progress as expected within the next 6-9 months.
Technical & market flow context
Technical indicators are mixed: short-term moving averages (10d and 20d) sit above current price, and RSI is near neutral at roughly 50, meaning the stock has room to move either way. Short interest and short-volume data show active trading interest from both shorts and longs; days-to-cover is low, which could amplify moves on positive news. Expect elevated volatility around test milestones and quarterly results.
Risks and counterarguments
Any investment here is not without meaningful downside. Key risks include:
- Execution risk on Neutron: The maiden flight is binary. A failed test or delayed schedule would almost certainly hit share price hard.
- Profitability and cash burn: Free cash flow is negative (recently -$316.3M). Continued cash burn could force dilution or expensive capital raises if operational milestones slip.
- Valuation sensitivity: The company trades at premium multiples. If growth slows or margins disappoint, multiple compression could erase gains even with revenue growth.
- Competition and pricing pressure: SpaceX and other launch providers exert downward pressure on launch prices and can win strategic customers.
- Macro & geopolitical: Rising rates or defense budget shifts could reduce demand or increase capital costs.
Counterargument: The market has likely already priced in successful commercialization of Neutron and much of the backlog’s value. If you believe the valuation already reflects a high-probability successful Neutron program, a more conservative approach is to wait for a post-test confirmation rally or to buy on a material pullback. That is a reasonable stance — this trade favors disciplined risk control and is predicated on conviction that the company executes the near-term plan.
Conclusion and what would change my mind
My current stance is to upgrade Rocket Lab to Buy with a disciplined long trade: entry $116.00, stop $95.00, and target $150.00 over a long-term (180 trading days) horizon. The investment case rests on scalable revenue growth (Q1: $200M, 63.5% YoY), a >$2B backlog providing multi-quarter visibility, and the potential for Neutron to open a materially larger market. These factors make the risk-reward attractive for a measured long position with tight risk controls.
I would change my view if any of the following occurred: a major technical failure or significant delay in the Neutron program, a reversal in backlog dynamics (cancellations or elongation of deliveries), or a sustained deterioration in cash flow that forces dilution at unfavorable terms. Conversely, proof points such as repeatable quarterly revenue beats, improving cash flow, or a successful Neutron test would strengthen the bull case and justify raising the target or moving to a longer-term core position.
Trade discipline matters here: Rocket Lab offers a high-reward path if milestones are met, but it remains a company where science, engineering and capital allocation execution will drive outcomes. Manage position size accordingly.